SCHEMBL2805055

SCHEMBL2805055

O=S(=O)(c1cccc(F)c1)N1CCc2c(cnc3[nH]ncc23)C1

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 7/20 0.44
TDP1 Q9NUW8 1/20 0.43
AKR1C1 Q04828 1/20 0.40
KMT2A Q03164 4/20 0.40
MEN1 O00255 3/20 0.40
POLB P06746 1/20 0.40
AKR1C2 P52895 1/20 0.39
PPARG P37231 1/20 0.39
PPARD Q03181 1/20 0.39
PPARA Q07869 1/20 0.39
PKM P14618 1/20 0.39
PKLR P30613 1/20 0.39
CHRM1 P11229 1/20 0.39
EGLN1 Q9GZT9 1/20 0.39
FAAH O00519 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2805056 0.88 AKR1C3 (0.44) AKR1C3AKR1C1KMT2AMEN1POLB
SCHEMBL2808596 0.88 MEN1 (0.45) AKR1C3AKR1C1KMT2AMEN1POLB
SCHEMBL2803231 0.87 MEN1 (0.51) KMT2AMEN1POLBPKMFAAH
SCHEMBL2802461 0.87 KDM4E (0.46) PPARGPPARDPPARAPKMPKLR
SCHEMBL2486484 0.87 MEN1 (0.51) AKR1C3AKR1C1KMT2AMEN1POLB
SCHEMBL2805569 0.87 KMT2A (0.43) KMT2AMEN1POLB
SCHEMBL2806316 0.85 AKR1C3 (0.46) AKR1C3AKR1C1KMT2AMEN1POLB
SCHEMBL2804355 0.85 AKR1C3 (0.47) AKR1C3PKMPKLR
SCHEMBL2807747 0.84 PKM (0.44) TDP1KMT2AMEN1PKMPKLR
SCHEMBL2802816 0.84 MKNK1 (0.46) KMT2APKMPKLR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
WO-2010078427-A1 SUBSTITUTED PYRAZOLO [3, 4-B] PYRIDINE COMPOUNDS ARQULE, INC. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS NQO1, IDH3B, IDH1 AKR1C3 1802/4885TDP1 1860/4885AKR1C1 1535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.